https://www.indianpharmapost.com/astrazeneca-pharma-india-receives-no-objection-for-durvalumab-137322023-02-17T00:00:00+05:30always0.9https://www.indianpharmapost.com/biocon-q3-fy23-revenue-up-36-137332023-02-17T00:00:00+05:30always0.9https://www.indianpharmapost.com/modernas-non-vaccine-mrna-therapeutic-set-to-generate-278-million-in-2028-if-approved-estimates-globaldata-137342023-02-17T00:00:00+05:30always0.9https://www.indianpharmapost.com/guerison-enters-indian-ophthalmology-market-137352023-02-17T00:00:00+05:30always0.9https://www.indianpharmapost.com/briefs-piramal-pharma-alembic-pharmaceuticals-137362023-02-17T00:00:00+05:30always0.9https://www.indianpharmapost.com/shilpa-medicare-unit-vi-bengaluru-facility-registered-with-ministry-of-health-uae-137372023-02-17T00:00:00+05:30always0.9https://www.indianpharmapost.com/lonza-completes-expansion-of-conjugation-facility-in-visp-137382023-02-17T00:00:00+05:30always0.9